Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of PM01183 as Second-line Treatment in Patients with Metastatic Pancreatic Cancer
2010-024292-30Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Mar 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in pancreatic cancer (PDAC), sponsored by PharmaMar. Primary endpoint: Overall Survival at 6 months (OS6). Started Mar 2011; status: completed.
02
Drugs
lurbinectedin
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2010-024292-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024292-30.